An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
The Japanese company urged Biden to reflect on the steps it has taken to address national-security concerns. One crew member was in intensive care after engine problems and smoke in the cabin and ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback